Immix Biopharma, Inc. (Nasdaq: IMMX) announced on March 30, 2026, that it has successfully completed enrollment for its NEXICART-2 clinical trial of NXC-201, a treatment for relapsed/refractory AL Amyloidosis. The company expects to release topline results in the third quarter of 2026, which will be followed by a Biologics License Application (BLA) submission and a planned commercial launch. This milestone aligns with the company's previous guidance and marks a significant step forward in its clinical development program. The NEXICART-2 trial is designed to evaluate the efficacy and safety of NXC-201, a CAR-T cell therapy that targets the underlying causes of AL Amyloidosis. The completion of enrollment is a critical phase in the trial, and the upcoming results are anticipated to provide valuable insights into the treatment's potential. Immix Biopharma has also onboarded a new Chief Medical Officer, Dr. Richard Graydon, who brings extensive experience from his previous roles at Merck and Johnson & Johnson. The company is optimistic about the future of NXC-201 and its potential to become the first FDA-approved treatment for this challenging condition. The AL Amyloidosis market is projected to grow significantly, and Immix is well-positioned to capitalize on this opportunity with its innovative therapies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.